Fecal Microbiota Transplants for Autism: What the Research Shows and What It Doesn’t

Headlines have described children whose autism symptoms seemed to fade after doctors transferred healthy gut bacteria into their intestines. The stories come from real research: a small clinical trial at Arizona State University in which children with autism and chronic digestive problems received an intensive fecal microbiota transplant program, followed by improvements in both gut and behavioral symptoms that persisted two years later. For parents of autistic children who struggle with constipation, diarrhea, and abdominal pain, the findings raised understandable hope.

But the research is earlier and more complicated than the headlines suggest. The trial had no placebo group, larger studies have questioned whether the gut microbiome causes autism-related differences at all, and fecal transplants carry real risks. This article explains what microbiota transfer therapy is, what studies have found, why scientists remain cautious, what randomized trials are testing now, and what families can do safely while the evidence develops.

Can fecal transplants treat autism? Not proven. A small 2017 open-label trial of fecal microbiota transplants (FMT) in autistic children reported improvements in gut and behavioral symptoms, generating excitement, but it had no placebo group and too few participants to be conclusive. Larger controlled trials are ongoing. FMT carries real risks, including serious infection, and should never be attempted at home or outside carefully supervised research.

What Is the Link Between Autism and the Gut?

Many autistic people experience gastrointestinal problems, and studies have found differences in their gut bacteria, prompting interest in whether the microbiome influences autism symptoms, though cause and effect remain unclear. Autism is a neurodevelopmental condition characterized by differences in social communication and by restricted or repetitive behaviors and interests. It is common: CDC surveillance published in 2025 by Kelly Shaw and colleagues found that among 8-year-olds in 16 U.S. communities in 2022, about 1 in 31 had been identified with autism, with prevalence 3.4 times higher in boys than girls. Many autistic people view autism as a natural variation in how brains work rather than a disease to be cured, while also seeking help with co-occurring problems that affect quality of life.

Gastrointestinal problems are among the most common of those co-occurring issues. Many autistic children experience chronic constipation, diarrhea, abdominal pain, and reflux, which can disrupt sleep, increase irritability, and be hard to communicate. Because GI symptoms often correlate with the intensity of behavioral challenges, researchers wondered whether gut bacteria might influence both. That idea sits within a broader field studying the gut-brain axis, the communication between intestinal microbes, the immune system, and the nervous system.

What Did Animal Studies Suggest?

Some mouse studies suggested that altering gut bacteria could affect behaviors resembling autism traits, which helped motivate human research, though animal findings often do not translate directly to people. Early clues came from mice. A 2013 study in Cell by Elaine Hsiao and colleagues at Caltech used a mouse model in which offspring of mothers with immune activation during pregnancy show some autism-like features. These mice had leaky intestinal barriers and altered gut bacteria. Treating them with a human gut bacterium, Bacteroides fragilis, corrected gut permeability and improved communicative, repetitive, anxiety-like, and sensorimotor behaviors. A 2019 follow-up in Cell by Gil Sharon and colleagues transplanted gut microbiota from autistic and non-autistic human donors into germ-free mice and found that mice receiving microbiota from autistic donors displayed more autism-like behaviors, with differences in gene splicing in the brain and in microbial metabolites. Mouse behaviors are imperfect stand-ins for human autism, and later analyses questioned some statistical aspects of the 2019 study, but the work encouraged clinical trials.

What Did the Arizona Fecal Transplant Trial Find?

A small 2017 open-label trial at Arizona State University gave FMT to 18 autistic children and reported improvements in GI and behavioral symptoms that persisted, but with no placebo group, the results are preliminary. The 2017 open-label trial, published in Microbiome by Dae-Wook Kang, James Adams, Rosa Krajmalnik-Brown, and colleagues, enrolled 18 children aged 7 to 16 with autism and moderate to severe chronic GI problems. The protocol, called microbiota transfer therapy, involved two weeks of an oral antibiotic, a bowel cleanse, a stomach acid suppressant, and then a fecal microbiota transplant from carefully screened healthy donors, beginning with a high initial dose and continuing with daily lower maintenance doses for seven to eight weeks. GI symptoms fell by about 80 percent by the end of treatment, including constipation, diarrhea, indigestion, and abdominal pain, and improvements persisted eight weeks later. Clinical assessments of autism-related behavior also improved significantly. Bacterial diversity increased, along with Bifidobacterium and Prevotella, and donor microbes partly took hold.

A two-year follow-up in Scientific Reports in 2019 found that most GI improvements were maintained in the same 18 participants and that autism-related symptom scores had improved further after treatment ended. Increased bacterial diversity and higher levels of Bifidobacteria and Prevotella also persisted. The authors concluded that the findings warranted a double-blind, placebo-controlled trial.

Why Scientists Remain Cautious

The Arizona results were encouraging, but the study design limits what can be concluded. With no placebo group, there is no way to know how much improvement came from the treatment itself versus other factors. Parents and clinicians knew every child was receiving the therapy, which can influence behavior ratings. Children develop and mature over two years, and relief from painful GI symptoms alone could improve sleep, mood, and behavior without any direct effect on autism. The protocol also combined several interventions, so even if it worked, it is unclear which part mattered. Eighteen participants is a small sample, and families who volunteer for intensive experimental treatments may differ from others. These are reasons for careful testing, not reasons to dismiss the findings.

Does the Gut Microbiome Actually Cause Autism?

Evidence suggests microbiome differences in autism may largely reflect diet and behavior rather than causing the condition; one study found gut differences tracked with restricted diets, not autism itself. A larger study challenged the idea that gut bacteria drive autism. A 2021 study in Cell by Chloe Yap and colleagues in Australia analyzed stool samples from 247 participants, including autistic children, their siblings, and unrelated children, using detailed genetic sequencing of gut microbes. They found negligible direct associations between autism diagnosis and the gut microbiome. Instead, autism-related restricted interests were associated with less diverse diets, which in turn were linked to reduced microbial diversity and looser stools. The authors concluded that microbiome differences in autism may reflect dietary preferences rather than cause autism features, and cautioned against claims that the microbiome plays a driving role. Researchers in the field continue to debate how to reconcile these findings with the mouse and transplant studies.

What Are the Risks of Fecal Transplants?

FMT can transmit infections, including serious and even fatal ones, and its long-term effects are not well understood, which is why it is tightly restricted and dangerous to attempt outside supervised medical research. Fecal microbiota transplantation is an established, FDA-regulated treatment for recurrent Clostridioides difficile infection, where it is highly effective. But transferring stool from one person to another can also transfer harmful microbes. A 2019 report in the New England Journal of Medicine by Zachariah DeFilipp and colleagues described two patients in separate clinical trials who developed bloodstream infections with drug-resistant E. coli after receiving FMT; both cases were traced to the same donor, and one patient died. The FDA subsequently required additional donor screening. Antibiotics used to prepare the gut also carry side effects. These risks are why FMT for conditions other than C. difficile should occur only in clinical trials with rigorous donor screening.

Do Not Try It at Home

Online forums sometimes describe do-it-yourself fecal transplants using stool from relatives or unscreened donors. Experts strongly warn against this. Without laboratory screening, stool can transmit bacteria, viruses, and parasites, including antibiotic-resistant organisms. Children are particularly vulnerable, and procedures such as enemas or repeated antibiotic courses can cause harm. Unregulated clinics offering FMT for autism outside of approved trials should also be avoided. Families interested in microbiome-based treatment should ask about enrolling in registered clinical trials.

Randomized Trials Now Under Way

Several placebo-controlled trials aim to answer whether microbiota therapy truly helps. The Arizona team has run phase 2 double-blind, placebo-controlled studies in children and adults with autism and GI symptoms. In New Zealand, the Gut Bugs in Autism Trial is testing oral capsules of fecal microbiome transfer against placebo in 100 autistic adolescents and adults aged 16 to 45 with GI symptoms; its protocol, published in 2024 in BMJ Open by Ry Tweedie-Cullen and colleagues, was designed in consultation with autism advisors and support organizations and focuses primarily on GI symptoms and well-being rather than on changing autism itself. A multicenter randomized trial in China is also testing FMT in children with autism and GI symptoms. Results from these trials will provide far stronger evidence than the original open-label study.

What Families Can Do Now

Concern	Evidence-based steps
Constipation or diarrhea	See a pediatrician or pediatric gastroenterologist; standard treatments such as stool softeners, fiber, and fluids are often effective
Restricted eating	Feeding therapy with an occupational therapist or dietitian experienced in autism; gradual introduction of new foods
Pain that is hard to communicate	Watch for behavior changes, sleep problems, or posturing that may signal GI discomfort; share observations with clinicians
Interest in microbiome therapy	Look for registered clinical trials; avoid unregulated clinics and home procedures
Probiotics	Discuss with a clinician; evidence for autism is limited and products vary

Diet Diversity and the Microbiome

If restricted eating shapes the microbiome, as the 2021 study suggested, expanding diet variety may be a safer way to support gut health. A diet including diverse fruits, vegetables, legumes, whole grains, and fermented foods feeds a broader range of gut bacteria. For many autistic children, sensory sensitivities make new foods difficult, so progress is gradual and guided by professionals who understand sensory and feeding challenges. Restrictive diets promoted for autism, such as gluten-free and casein-free diets, have not shown consistent benefits in controlled trials and can further narrow food variety, so they should be considered only with clinical guidance, such as when a child has celiac disease or a confirmed food allergy.

Probiotics and Other Microbiome Products

Probiotic supplements are widely marketed for autism. Small trials have tested various strains with mixed results, and systematic reviews have generally found the evidence insufficient to recommend probiotics for core autism features, though some studies suggest possible benefits for GI symptoms. Probiotic products vary widely in strains, doses, and quality, and they are regulated as dietary supplements rather than drugs. Families considering probiotics should discuss them with a clinician, choose products from reputable manufacturers, and monitor for any changes.

Respecting Autistic Perspectives

Discussions of autism treatment increasingly include the perspectives of autistic people themselves. Many autistic adults emphasize that autism is part of their identity and that research should focus on improving quality of life, such as relieving GI pain, anxiety, and sleep problems, rather than eliminating autistic traits. The New Zealand trial reflects this shift by prioritizing GI symptoms and well-being and involving autistic advisors in its design. Framing microbiome research around health and comfort, rather than cure, may better serve autistic people and their families.

Why Headlines Overstate Early Findings

Stories describing autism symptoms that “disappear” after a treatment attract attention but often overstate preliminary research. Small, uncontrolled studies are the first step in testing a new idea; many promising early results fail to hold up in larger, controlled trials. Parents seeking help for their children are especially vulnerable to overstated claims and to clinics that sell unproven treatments. Looking for information about study design, sample size, control groups, and whether results have been replicated helps distinguish genuine progress from hype.

How the Gut and Brain Communicate

The gut and brain communicate through several pathways. The vagus nerve carries signals between the intestines and the brainstem. Gut bacteria produce metabolites, such as short-chain fatty acids, and influence levels of molecules involved in signaling, including precursors of serotonin. The immune system, much of which resides in the gut, responds to microbes and can affect inflammation throughout the body. These pathways explain why researchers think gut microbes could influence mood, behavior, and stress responses, though translating this biology into effective treatments for people has proven challenging across many conditions.

A Balanced View

Microbiota transfer therapy produced striking improvements in GI symptoms and autism-related behavior ratings in a small, uncontrolled trial, with gains lasting two years. Animal studies support the idea that gut microbes can influence behavior. However, a larger human study suggested that microbiome differences in autism largely reflect diet, fecal transplants carry infection risks, and the original trial had no placebo group. Placebo-controlled trials now under way will clarify whether microbiome therapy helps, particularly for the GI symptoms that affect many autistic people. In the meantime, families should pursue proven treatments for GI problems and avoid unregulated or home procedures.

Practical Takeaways

Take GI symptoms seriously in autistic children and seek evaluation from a pediatrician or gastroenterologist. Work with feeding specialists to gradually expand diet variety. Do not attempt home fecal transplants or use unregulated clinics. If interested in microbiome therapy, look for registered clinical trials. Discuss probiotics or special diets with clinicians before starting them. Be cautious about headlines claiming cures from small studies.

Fecal Transplants Where They Work: C. difficile

FMT’s reputation comes largely from its success against recurrent Clostridioides difficile infection, a severe, sometimes life-threatening bowel infection that often follows antibiotic use. For patients with repeated recurrences, transplanting healthy donor microbiota cures the infection in a large majority of cases, far outperforming antibiotics alone. In 2022 and 2023, the FDA approved the first standardized microbiome-based products for preventing recurrent C. difficile, one given rectally and one as oral capsules. This success shows that changing the microbiome can treat disease when a clear microbial cause exists. For autism, where the role of microbes is far less clear, the same confidence does not yet apply.

Why GI Symptoms Matter So Much

Even if microbiome therapy does not change autism itself, the GI findings matter. Chronic constipation, diarrhea, and abdominal pain cause real suffering and can affect sleep, attention, mood, and behavior, particularly in children who cannot easily describe pain. Some behaviors interpreted as autism-related, such as aggression, self-injury, or sleep disruption, may sometimes reflect untreated discomfort. Clinical guidelines encourage clinicians to evaluate GI symptoms in autistic children carefully. Improving digestive health through medical care, diet, and possibly future microbiome therapies could meaningfully improve quality of life regardless of effects on core autism traits.

Questions to Ask About Any New Autism Treatment

Has the treatment been tested in randomized, placebo-controlled trials? How many participants were studied, and were results replicated by independent researchers? What are the risks and costs? Is the treatment offered through a registered clinical trial or a regulated clinical service? Does it aim to improve health and quality of life, or does it promise to cure autism? Is the provider selling the treatment or related products? These questions help families evaluate claims and protect children from harmful or wasteful interventions.

Looking Ahead

Results from placebo-controlled trials over the next few years will show whether microbiome-based therapy can reliably improve GI symptoms or other outcomes in autistic people. Researchers are also developing defined bacterial consortia and microbial metabolite treatments that could be safer and more standardized than whole stool. Studies combining microbiome, diet, and genetic data may clarify which individuals, if any, are most likely to benefit. Until then, the most responsible approach is to view microbiota therapy as promising but unproven, to treat digestive problems with established methods, and to follow trial results as they are published.

Sleep, Behavior, and Digestive Comfort

Sleep problems are common among autistic children and are often linked with GI discomfort. Constipation and reflux can worsen at night, disrupting sleep, which in turn affects daytime mood, attention, and behavior. In the Arizona trial, improvements in GI symptoms may have contributed to better sleep and behavior, which is one reason researchers want controlled studies to disentangle these effects. Families noticing sleep problems alongside digestive symptoms should mention both to their child’s clinician, since treating one may help the other.

The Costs of Experimental Treatments

Unproven autism treatments can be expensive, and families sometimes travel abroad to clinics offering fecal transplants or other experimental therapies outside regulated trials. Beyond financial strain, such treatments may involve unscreened donors, inadequate medical monitoring, and no follow-up care. Registered clinical trials, by contrast, are typically free to participants, follow strict safety protocols, and contribute knowledge that benefits others. Families can search public clinical trial registries to find legitimate studies.

Supporting the Whole Child

Focusing on a single treatment can distract from the broader supports that help autistic children thrive. Evidence-based approaches include speech and language therapy, occupational therapy for sensory and motor needs, social communication supports, educational accommodations, and treatment of co-occurring conditions such as anxiety, ADHD, sleep problems, and GI disorders. Supporting parents and caregivers, connecting families with autistic adults and community organizations, and respecting the child’s interests and communication style also matter. GI care fits within this larger picture as one important part of overall well-being.

Common Myths

“Fecal transplants cure autism.” A small uncontrolled trial reported improvements; placebo-controlled trials have not yet confirmed benefits.

“Gut bacteria cause autism.” Autism is largely genetic and developmental; a large study found microbiome differences mostly reflect diet.

“Fecal transplants are risk-free because they are natural.” They can transmit dangerous infections, and one patient died after a contaminated transplant.

“Any probiotic will help.” Evidence for probiotics in autism is limited, and products vary widely.

“GI problems are just part of autism.” GI symptoms are common but treatable, and addressing them can improve comfort and quality of life.

Key Terms

Microbiota transfer therapy (MTT): An intensive protocol combining antibiotics, a bowel cleanse, and repeated fecal microbiota transplants.

Fecal microbiota transplantation (FMT): Transferring stool from a screened healthy donor to a recipient to change gut bacteria.

Gut-brain axis: Communication between gut microbes, the immune system, and the nervous system.

Open-label trial: A study in which participants and researchers know who receives treatment, without a placebo.

Germ-free mice: Mice raised without any microbes, used to study the effects of specific microbiota.

The Bottom Line

Reports of autism symptoms fading after a doctor’s treatment refer to microbiota transfer therapy, an intensive fecal transplant protocol tested in a 2017 open-label trial of 18 autistic children with chronic GI problems. GI symptoms dropped by about 80 percent and behavior ratings improved, with benefits lasting two years. But the study had no placebo group, a larger 2021 study found that microbiome differences in autism mainly reflect restricted diets, and fecal transplants can transmit dangerous infections. Placebo-controlled trials are under way. For now, families should treat GI symptoms through qualified clinicians, work on diet variety with feeding specialists, avoid home or unregulated transplants, and consider registered clinical trials if interested in microbiome therapy.

Frequently Asked Questions

Can fecal transplants help autism?

There is no proven evidence that fecal microbiota transplants (FMT) treat autism. A small 2017 open-label trial reported improvements in gastrointestinal and behavioral symptoms in autistic children, which drew attention, but it lacked a placebo group and had too few participants to draw firm conclusions. Larger, controlled trials are underway. For now, FMT is experimental for autism and should only be considered within carefully supervised research.

What did the autism fecal transplant study actually show?

The 2017 study from Arizona State University gave fecal transplants to 18 autistic children with GI problems and reported reductions in digestive and behavioral symptoms that lasted after treatment. While encouraging, the trial was small and open-label, meaning there was no placebo comparison and everyone knew they received treatment. This design cannot rule out placebo effects or other explanations, so the findings are preliminary rather than definitive proof.

Does the gut microbiome cause autism?

The relationship is not well understood, and current evidence does not show that gut bacteria cause autism. While autistic people often have different gut microbiomes, research suggests these differences may largely result from restricted diets and eating behaviors common in autism, rather than causing the condition. One study found that microbiome differences tracked with diet, not autism itself, cautioning against assuming the gut drives autism.

Is it safe to try a fecal transplant for autism at home?

No. Attempting a fecal transplant at home is dangerous and strongly discouraged. FMT can transmit serious infections, and cases of severe harm, including death, have occurred even in medical settings. Donor stool requires careful screening, and the long-term effects of changing the microbiome are not fully known. FMT for autism remains experimental and should only ever happen within a regulated clinical trial under medical supervision.

Are there ongoing studies on fecal transplants and autism?

Yes. Following the small early trial, larger and more rigorous studies, including placebo-controlled trials, have been launched to test whether FMT or microbiome-based treatments genuinely help autistic people with GI or behavioral symptoms. These studies aim to provide the controlled evidence the first trial lacked. Until they are completed, any claims that fecal transplants effectively treat autism are premature and not supported by solid scientific proof.

References

1. Shaw KA, Williams S, Patrick ME, et al. Prevalence and Early Identification of Autism Spectrum Disorder Among Children Aged 4 and 8 Years – Autism and Developmental Disabilities Monitoring Network, 16 Sites, United States, 2022. MMWR Surveillance Summaries. 2025;74(2):1–22. PMID 40232988
2. Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451–1463. PMID 24315484
3. Sharon G, Cruz NJ, Kang DW, et al. Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice. Cell. 2019;177(6):1600–1618.e17. PMID 31150625
4. Kang DW, Adams JB, Gregory AC, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5(1):10. PMID 28122648
5. Kang DW, Adams JB, Coleman DM, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Scientific Reports. 2019;9(1):5821. PMID 30967657
6. Yap CX, Henders AK, Alvares GA, et al. Autism-related dietary preferences mediate autism-gut microbiome associations. Cell. 2021;184(24):5916–5931.e17. PMID 34767757
7. DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. New England Journal of Medicine. 2019;381(21):2043–2050. PMID 31665575
8. Tweedie-Cullen RY, Leong K, Wilson BC, et al. Protocol for the Gut Bugs in Autism Trial: a double-blind randomised placebo-controlled trial of faecal microbiome transfer for the treatment of gastrointestinal symptoms in autistic adolescents and adults. BMJ Open. 2024;14(2):e074625. PMID 38320845

Last updated: October 6, 2026